The discovery of immune checkpoint pathways such as CTLA4 and PD1/PDL1, which control T-cell activation and activity, has fuelled interest in their modulation to achieve sustained anti-tumor immunity. This requires sufficient T-cell infiltration and activity in tumors. However, these processes are incompletely understood, in part due to the terminal nature of current analysis techniques. We therefore optimized labeling of activated T-cells with iron oxide nanoparticles, transferred labeled T-cells into tumor bearing hosts and performed serial MRI. Although, hypointense spots could be detected in the tumor rim following T-cell transfer, quantification is complicated by vascular abnormality induced susceptibility changes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords